One of the world’s leading microbiome scientists is to present OptiBiotix Health plc’s (LON:OPTI) latest research at a large industry conference in San Diego next week.
Professor Bob Rastall will speak at the Microbiome R&D and Business Collaboration on November 2-3.
Opti’s technology can boost health benefits of probiotics
The presentation will cover the work carried out by Opti alongside the University of Reading on OptiBiotics – combinations of a probiotic and a targeted prebiotic that enhance the health benefits of typical probiotic products.
READ: Optibiotix ties with Spain's Galenicum to extend reach of microbiome-based cholesterol reducer
Opti said the new product concept is a “more rational and scientific approach” to develop optimised synbiotics – when a product contains a prebiotic and probiotic – that boost a product’s health benefits in a market estimated to be worth almost US$50bn by 2020.
Rastall will also present research on how OptiBiotix has been able to enhance the cholesterol-reducing effect of its LPLDL strain.
Presentations grow credibility of research
“These presentations at major international conferences are important steps in establishing the scientific maturity and credibility of our technologies,” said Opti chief executive Stephen O’Hara.
“We are particularly pleased that Professor Bob Rastall, one of the world’s leading scientists in this field is presenting the research which was undertaken under his leadership at the University of Reading.”
He added: “The last 12 months has seen an increase in the number of presentations and publications on OptiBiotix's research reflecting the growing interest and maturity of our science.
“These presentations and publications help build awareness of OptiBiotix's technology and products in international markets and provide the scientific evidence base to support commercialisation of our next generation prebiotics, probiotics, and OptiBiotic products.”